金砖扩容后市场潜力大爆发，中国生物医药、AI 企业如何抢占先机？

Core Viewpoint - The article highlights the new phase of Chinese enterprises going global, focusing on technology empowerment and ecosystem building, in the context of global industrial chain restructuring and China's "dual circulation" strategy [1] Group 1: Event Overview - The "Beijing Technology Innovation Enterprises Going Global Exchange Conference" was held on May 30, 2025, in Beijing, organized by NICTC and the BRICS Technology Transfer Center, aimed at helping Chinese tech companies expand into international markets [1] - The event focused on cutting-edge fields such as biomedicine and artificial intelligence, featuring representatives from countries like the UAE, Mexico, Russia, and South Africa, and included policy interpretation, case sharing, resource matching, and corporate roadshows [3] Group 2: Market Potential and Trends - The BRICS countries, after expansion, now represent nearly 50% of the global population and over 30% of global GDP, with expectations to exceed 40% this year, providing significant market opportunities for new technologies [7] - The emphasis on cooperation among BRICS nations is seen as crucial for leveraging the Fourth Industrial Revolution, particularly in biomedicine and artificial intelligence, which are identified as key technological directions for future development [6][10] Group 3: Successful Experiences and Mechanisms - NICTC has been actively promoting cooperation in innovation and entrepreneurship among BRICS countries, achieving notable results through joint research projects and a multi-faceted approach to technology transfer [8][9] - The establishment of a cross-national technology achievement database has gathered over 4,000 technology results from China and BRICS countries, enhancing the efficiency of technology transfer through localized managers [9] Group 4: Case Studies and Innovations - A successful technology transfer case involved a collaboration between a Beijing enterprise and Russia for HPV vaccine technology, which generated annual orders of $100 million and exemplified effective cooperation in the biomedicine sector [12] - Chinese enterprises in biomedicine and artificial intelligence are recognized for their significant advancements, with domestic innovations in areas like tumor treatment and AI technologies attracting interest from BRICS nations [10][11] Group 5: Future Directions - NICTC aims to provide comprehensive solutions for biomedicine and AI companies facing resource and funding challenges, integrating BRICS resources to create a full-chain ecosystem for technology transfer and cross-border financing [13]